BRPI0820657A2 - Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza - Google Patents

Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza

Info

Publication number
BRPI0820657A2
BRPI0820657A2 BRPI0820657-0A BRPI0820657A BRPI0820657A2 BR PI0820657 A2 BRPI0820657 A2 BR PI0820657A2 BR PI0820657 A BRPI0820657 A BR PI0820657A BR PI0820657 A2 BRPI0820657 A2 BR PI0820657A2
Authority
BR
Brazil
Prior art keywords
propanamides
fluorobenzyloxy
benzylamino
production
high purity
Prior art date
Application number
BRPI0820657-0A
Other languages
English (en)
Inventor
Elena Barbanti
Patricia Salvati
Renato Canevotti
Francesco Ponzini
Laura Faravelli
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of BRPI0820657A2 publication Critical patent/BRPI0820657A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
BRPI0820657-0A 2007-12-11 2008-12-01 Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza BRPI0820657A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07023937 2007-12-11
PCT/EP2008/066559 WO2009074478A1 (en) 2007-12-11 2008-12-01 Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree

Publications (1)

Publication Number Publication Date
BRPI0820657A2 true BRPI0820657A2 (pt) 2015-06-16

Family

ID=39301684

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820657-0A BRPI0820657A2 (pt) 2007-12-11 2008-12-01 Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza

Country Status (27)

Country Link
US (2) US8530701B2 (pt)
EP (2) EP2229351B1 (pt)
JP (2) JP5460613B2 (pt)
KR (2) KR101709498B1 (pt)
CN (2) CN101896456B (pt)
AR (1) AR071267A1 (pt)
AU (1) AU2008334778B2 (pt)
BR (1) BRPI0820657A2 (pt)
CA (2) CA2706789C (pt)
CY (1) CY1119991T1 (pt)
DK (1) DK2229351T3 (pt)
EA (2) EA030250B1 (pt)
ES (2) ES2837000T3 (pt)
HK (2) HK1145673A1 (pt)
HR (1) HRP20180210T1 (pt)
HU (1) HUE036232T2 (pt)
IL (1) IL205872A (pt)
LT (1) LT2229351T (pt)
MX (1) MX2010006278A (pt)
NO (1) NO2229351T3 (pt)
NZ (1) NZ585806A (pt)
PL (1) PL2229351T3 (pt)
PT (1) PT2229351T (pt)
RS (1) RS56803B1 (pt)
SI (1) SI2229351T1 (pt)
TW (1) TWI429425B (pt)
WO (1) WO2009074478A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
AU2007263328C1 (en) * 2006-06-19 2012-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
EP2229351B1 (en) * 2007-12-11 2017-11-08 Newron Pharmaceuticals S.p.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
HUE030504T2 (en) * 2010-04-27 2017-05-29 Newron Pharm Spa Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers
EP2638007A2 (en) 2010-11-11 2013-09-18 Redx Pharma Limited Drug derivatives
CN103044279B (zh) * 2012-12-21 2015-07-08 苏州永健生物医药有限公司 一种n-香豆酰多巴胺的合成方法
WO2015102390A1 (ko) * 2013-12-30 2015-07-09 이화여자대학교 산학협력단 신규한 아미드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 통증의 예방 또는 치료용 약학적 조성물
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106565442B (zh) * 2016-08-24 2019-07-16 浙江美诺华药物化学有限公司 3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛的制备方法
CN106349269B (zh) * 2016-08-24 2018-08-31 浙江美诺华药物化学有限公司 2-(3-氟苄氧基)-5-甲酰基苯硼酸及其制备方法
CN106632223B (zh) * 2016-08-24 2019-04-23 浙江美诺华药物化学有限公司 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
WO2020136671A1 (en) * 2018-12-27 2020-07-02 Natco Pharma Limited Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
US11111208B2 (en) * 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
US11225457B2 (en) * 2019-08-06 2022-01-18 Medichem, S.A. Process for preparing safinamide
CN113444010B (zh) * 2020-03-28 2023-09-05 南京正大天晴制药有限公司 一种沙芬酰胺有关物质的制备方法
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
MXPA02009619A (es) * 2000-03-31 2004-07-30 Eruro Celtique S A Aminopiridinas y su uso como anticonvulsivos y bloqueadores del canal de sodio.
ES2253579T3 (es) 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
AU2004266494B2 (en) 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CN101018546B (zh) 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
AU2007263328C1 (en) * 2006-06-19 2012-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
EP2229351B1 (en) * 2007-12-11 2017-11-08 Newron Pharmaceuticals S.p.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree

Also Published As

Publication number Publication date
CN104523668A (zh) 2015-04-22
IL205872A (en) 2015-06-30
JP6023727B2 (ja) 2016-11-09
EA201400105A1 (ru) 2014-05-30
JP2011506375A (ja) 2011-03-03
KR101593627B1 (ko) 2016-02-11
AU2008334778B2 (en) 2013-05-23
US20100324141A1 (en) 2010-12-23
EP3257842A1 (en) 2017-12-20
ES2837000T3 (es) 2021-06-29
CN101896456B (zh) 2014-10-22
WO2009074478A1 (en) 2009-06-18
RS56803B1 (sr) 2018-04-30
CA2706789C (en) 2016-09-06
AU2008334778A2 (en) 2010-07-08
EP2229351B1 (en) 2017-11-08
JP2014159407A (ja) 2014-09-04
HRP20180210T1 (hr) 2018-03-09
HK1204960A1 (en) 2015-12-11
TW200932209A (en) 2009-08-01
US8530701B2 (en) 2013-09-10
HK1145673A1 (en) 2011-04-29
EA201070719A1 (ru) 2010-12-30
EP3257842B1 (en) 2020-11-18
LT2229351T (lt) 2018-01-25
PL2229351T3 (pl) 2018-04-30
KR20100103571A (ko) 2010-09-27
JP5460613B2 (ja) 2014-04-02
CA2936209C (en) 2020-02-11
AU2008334778A1 (en) 2009-06-18
SI2229351T1 (en) 2018-02-28
DK2229351T3 (en) 2018-01-22
IL205872A0 (en) 2010-11-30
NO2229351T3 (pt) 2018-04-07
US8846763B2 (en) 2014-09-30
AR071267A1 (es) 2010-06-09
EA019898B1 (ru) 2014-07-30
EA030250B1 (ru) 2018-07-31
NZ585806A (en) 2011-09-30
US20140051758A1 (en) 2014-02-20
HUE036232T2 (hu) 2018-06-28
TWI429425B (zh) 2014-03-11
CN101896456A (zh) 2010-11-24
ES2655706T3 (es) 2018-02-21
EP2229351A1 (en) 2010-09-22
PT2229351T (pt) 2018-01-19
KR101709498B1 (ko) 2017-02-23
CN104523668B (zh) 2020-06-09
CA2936209A1 (en) 2009-06-18
KR20160017140A (ko) 2016-02-15
CY1119991T1 (el) 2018-12-12
MX2010006278A (es) 2010-08-31
CA2706789A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
BRPI0820657A2 (pt) Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza
HK1130245A1 (en) Process for the production of 2-[4-(3-and 2-fluorobenzyloxy) benzylamino] propanamides
BRPI0816253A2 (pt) Processo para a produção de um produto de hidrocarboneto
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI0921408B8 (pt) processo para a fabricação de (r)-2-acetamido-n-benzil-3-metoxipropion-amida (i) opticamente pura
BRPI0815825A2 (pt) Processo para a produção de um óxido de olefina
BRPI0914788A2 (pt) Processo para a produção de um produto intermediário de etexilato de dabigatran
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0913622A2 (pt) Processo para a produção fermentativa de eritropoietina
BRPI0810238A2 (pt) Processo para produção de pcc
BRPI0812304A2 (pt) Processo para a produção de p4o6
BRPI0811644A2 (pt) Processo para a produção de pirazóis
BRPI1010128A2 (pt) "processo para a fabricação do 2,3,3,3 - tetrafluropropeno"
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0814012A2 (pt) Processo para produção de (met)acrilatos
BRPI0818541A2 (pt) Processo para a produção de um produto farmacêutico
BR112013001111A2 (pt) processo para a produção do composto da fórmula 1, processo para a produção de um composto da fórmula a, processo para a produção dos compostos da fórmula d, composto da fórmula e, composto da fórmula f e novos compostos
BRPI0921736A2 (pt) processo para a fabricação de p4o6 com alto rendimento
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0908900A2 (pt) processo para a produção de polióis
BRPI0821837A2 (pt) Processo para a preparação de 6-substituídas-1-(2h)-isoquinolinonas
BRPI0719180A2 (pt) Processo para produzir um composto dialquil estanho
BRPI0920705A2 (pt) processo para a produção de compostos aquilaromáticos
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0914400A2 (pt) "processo para a síntese de um composto"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: NEWRON PHARMACEUTICALS S.P.A. (IT)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]